Use of specimen mammography-guided FNA (fine-needle aspirates) for flow cytometric multiple marker analysis and immunophenotyping in breast cancer

Abstract

A pilot study of a novel translational research method to simultaneously assay multiple molecular markers and DNA in fine‐needle aspirates (FNA) of mammographically detected breast lesions is described. Specimen mammography‐guided 20‐gauge FNAs obtained from 86 lesions and 22 areas of normal tissue were analyzed by multiparameter flow cytometry for DNA content, her2/neu, transforming growth factor α (TGFα), and the epithelial marker cytokeratin (CK) simultaneously. Epithelial cell her2/neu positivity was detected in 12 of 44 (27%) of invasive ductal carcinomas and 3 of 9 (33%) ductal carcinoma in situ (DCIS), 10 of 30 (33%) benign lesions, and 4 of 22 (18%) normal tissue aspirates. All lesions and normal tissue showed a similar positive rate for TGFα ranging from 61 to 76%. The CK+TGFα−her2/neu+ immunophenotype was more frequently positive in aneuploid tumors (22%) than all other lesions (7%) (P < 0.05). Specimen mammography‐guided FNAs provide fresh cells for flow cytometric multiple marker analysis and immunophenotyping of clinically occult breast lesions and normal tissue. Cytometry (Comm. Clin. Cytometry) 42:165–173, 2000. © 2000 Wiley‐Liss, Inc.

Measurement of conatumumab‐induced apoptotic activity in tumors by fine needle aspirate sampling

“…As indicated by the mixed effect model analysis of the FNA data, most of the variability was contributed by intra‐animal (or intra‐tumor) variation, suggesting that eight to ten replicates for each tumor would provide a reliable result. In clinical practice, this number of FNAs would not be feasible, and FNA sampling coupled with more sophisticated imaging techniques such as endoscopic ultrasound‐guided or mammography‐guided FNAs may be required to reduce variability (25, 41). Further investigation on FNA collection methodology is underway to maximize the sampling area from a single FNA procedure.…”

Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with 64Cu-DOTA-trastuzumab

“…Since HER-2 is a key client protein of HSP90, analyzing the expression status of HER-2 will be of great help in anti-tumor therapy with HSP90 inhibitors including 17-DMAG. Traditionally, analyzing of HER-2 overexpression in surgical specimens is most commonly accomplished by either immunohistochemical (IHC) staining or fluorescence in-situ hybridization (FISH) testing [25, 26]. Despite the preselection for HER-2 overexpression based on IHC staining or FISH of a tumor biopsy, only 11-35% of patients in phase II trials responded to trastuzumab when it was given as a single agent [27].…”

Non-Invasive PET Imaging of EGFR Degradation Induced by a Heat Shock Protein 90 Inhibitor

“…Accurate evaluation of the EGFR status in tumors will provide guidance for EGFR targeted therapy either by antibodies [9] or tyrosine kinase inhibitors (TKIs) [10]. Analyzing the overexpression of EGFR in surgical specimens is most commonly accomplished by either immunohistochemical (IHC) staining or fluorescence in situ hybridization testing [11,12]. Currently, various noninvasive molecular imaging modalities are under intensive investigation to provide the comprehensive diagnostic information that can improve patient management [13,14].…”